v3.25.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Research and development (“R&D”) expenses, net $ 24,663 $ 16,698
General and administrative expenses 11,776 8,650
Goodwill impairment 801
IPR&D impairment 3,237
Long-lived assets impairment 4,046
Operating loss 44,523 25,348
Other income (2,143) (357)
Interest expenses 873 2,404
Finance expense (income), net 919 (1,249)
Income from change in fair value of Private Placement Warrants (26,458)
Loss before tax 17,714 26,146
Tax expenses 13 23
Net Loss $ 17,727 $ 26,169
Basic loss per share of Common Stock (in Dollars per share) $ 1.47 $ 5.1
Diluted loss per share of Common Stock (in Dollars per share) $ 3.36 $ 5.1
Weighted average number of shares used in computing basic loss per share of Common Stock (in Shares) [1] 12,019,401 5,133,093
Weighted average number of shares used in computing diluted loss per share of Common Stock (in Shares) [1] 13,138,106 5,133,093
[1] All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split as discussed in Note 12A.

Source